ForteBio Inc.
http://www.fortebio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ForteBio Inc.
Ascletis Raises Mammoth $100 Million To Deploy Its US-China Hybrid Model
In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding.
Medtech Venture Investing 2010: Do the Right Thing
In March 2010, Elsevier Business Intelligence convened a panel of venture capitalists and CEOs of devicestart-ups to discuss the climate for early and late stage funding. Their conclusion: there is money out there, if companies do the right things.
Investing In China: Views from Windhover's PharmAsia Summit
A recap of the first annual PharmAsia Summit, outlining current views on the opportunities and risks associated with investing in China.
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2008
Highlights from the Q3 2008 review of device and diagnostics dealmaking: Led by late-stage rounds, financing for medical device firms--at just over $1bn--showed a slight improvement over the last quarter. IPOs and follow-ons were noticeably absent in Q3, reminiscent of a time in 2003 when the IPO window closed. Not even one of the 13 device M&A transactions reached the billion-dollar mark, but the largest deal, GE Healthcare's buy of Vital Signs for $990mm, came close. In vitro diagnostics/research financings doubled to $643mm led by Illumina's $343mm FOPO. M&A activity in this industry was scant with a mere three transactions. However, Nanogen's reverse merger with Elitech Group--worth $99mm-beat the median M&A deal price ($60mm) over the past five years. Interestingly many in vitro diagnostics players turned to alliances with tech transfer entities in hopes of filling their pipelines.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice